Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1690010.36691/RJA16900EditorialРедакционная статьяEditorialMoisturizers for the treatment and prophylaxis of atopic dermatitis exacerbationsРоль эмолентов в лечении и профилактике развития обострений атопического дерматитаhttps://orcid.org/0000-0003-0006-27732497-5608ChernushevichDaria D.ЧернушевичДарья Дмитриевна
Russian Federation
chernushevitchdasha@yandex.ruhttps://orcid.org/0000-0001-8254-97154146-1788ShtyrbulOlga V.ШтырбулОльга Владимировна
Russian Federation

MD, Cand. Sci. (Med.)

канд. мед. наук

ovs-495@yandex.ruhttps://orcid.org/0000-0002-0756-54646726-3997GrebenchenkoElena I.ГребенченкоЕлена Игоревна
Russian Federation

MD, Cand. Sci. (Med.)

канд. мед. наук

ghellena@mail.ruhttps://orcid.org/0000-0003-3358-50875012-7242FedenkoElena S.ФеденкоЕлена Сергеевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д-р мед. наук, профессор

efedks@gmail.comNational Research Center ― Institute of Immunology Federal Medical-Biological Agency of RussiaГосударственный научный центр «Институт иммунологии»21122023021220232045495553110202307112023Copyright ©; 2023, Pharmarus Print MediaCopyright ©; 2023, Фармарус Принт Медиа2023Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/16900

Atopic dermatitis is a global problem with increasing prevalence. Genetic predisposition to allergies, epidermal barrier dysfunction, and T2 immune response underlie atopic dermatitis. Xerosis, itchy skin, and exacerbation are the main atopic dermatitis symptoms, leading to increased permeability of allergens and microbes through the damaged epidermis and to the development of sensitization. The main purpose of atopic dermatitis therapy is to achieve long-term remission and improve quality of life. Topical treatment includes glucocorticosteroids, topical calcineurin inhibitors, and emollients to reduce inflammation, xerosis, and infection prevention. Daily use of effective emollients as basic skin care can improve epidermal barrier function, provide skin hydration, and reduce the need for topical glucocorticosteroids.

Атопический дерматит представляет глобальную проблему для практического здравоохранения, частота распространённости которого увеличивается с каждым годом во всём мире. В основе атопического дерматита лежит генетическая предрасположенность к развитию аллергии, нарушению функции эпидермального барьера и развитию Т2-воспаления. Сухость кожи, или ксероз, наряду с кожным зудом и поражением кожи является одним из основных симптомов атопического дерматита, приводит к повышенной проницаемости аллергенов и микробов через повреждённый эпидермис и развитию сенсибилизации.

Основными целями терапии атопического дерматита являются контроль над симптомами заболевания, достижение длительной ремиссии и улучшение качества жизни. Наружная терапия атопического дерматита включает применение топических глюкокортикоидов, топических ингибиторов кальциневрина и эмолентов и направлена на подавление воспаления, уменьшение сухости кожи, борьбу с инфицированием. Ежедневное использование современных эффективных эмолентов в качестве базового ухода за кожей улучшает функцию эпидермального барьера, обеспечивает эффективное увлажнение, восполняет дефицит липидов в коже, уменьшает использование топических глюкокортикоидов.

atopic dermatitisepidermal barriertopical treatmentskin careemollientsатопический дерматитэпидермальный барьернаружная терапияуход за кожейэмолентыMaspero J, De Paula Motta Rubini N, Zhang J, et al. Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey. World Allergy Organ J. 2023;16(3):100724. doi: 10.1016/j.waojou.2022.100724Maspero J., De Paula Motta Rubini N., Zhang J., et al. Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey // World Allergy Organ J. 2023. Vol. 16, N 3. Р. 100724. doi: 10.1016/j.waojou.2022.100724Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick update. Ann Allergy Asthma Immunol. 2023;130(6):811–820. doi: 10.1016/j.anai.2023.03.010Boguniewicz M., Fonacier L., Guttman-Yassky E., et al. Atopic dermatitis yardstick update // Ann Allergy Asthma Immunol. 2023. Vol. 130, N 6. Р. 811–820. doi: 10.1016/j.anai.2023.03.010Kang SY, Um JY, Chung BY, et al. Moisturizer in patients with inflammatory skin diseases. Medicina (Kaunas). 2022;58(7):888. doi: 10.3390/medicina58070888Kang S.Y., Um J.Y., Chung B.Y., et al. Moisturizer in patients with inflammatory skin diseases // Medicina (Kaunas). 2022. Vol. 58, N 7. Р. 888. doi: 10.3390/medicina58070888Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e7. doi: 10.1016/j.jaad.2018.05.1241Lee H.H., Patel K.R., Singam V., et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis // J Am Acad Dermatol. 2019. Vol. 80, N 6. Р. 1526–1532e7. doi: 10.1016/j.jaad.2018.05.1241Abuabara K, Yu AM, Okhovat JP, et al. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73(3):696–704. doi: 10.1111/all.13320Abuabara K., Yu A.M., Okhovat J.P., et al. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies // Allergy. 2018. Vol. 73, N 3. Р. 696–704. doi: 10.1111/all.13320Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1Langan S.M., Irvine A.D., Weidinger S. Atopic dermatitis // Lancet. 2020. Vol. 396, N 10247. Р. 345–360. doi: 10.1016/S0140-6736(20)31286-1Aw M, Penn J, Gauvreau GM, et al. Atopic march: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958Aw M., Penn J., Gauvreau G.M., et al. Atopic march: Collegium Internationale Allergologicum Update 2020 // Int Arch Allergy Immunol. 2020. Vol. 181, N 1. Р. 1–10. doi: 10.1159/000502958Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi: 10.1016/j.anai.2017.10.037Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance // Ann Allergy Asthma Immunol. 2018. Vol. 120, N 2. Р. 131–137. doi: 10.1016/j.anai.2017.10.037Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004Czarnowicki T., Krueger J.G., Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march // J Allergy Clin Immunol. 2017. Vol. 139, N 6. Р. 1723–1734. doi: 10.1016/j.jaci.2017.04.004Aaron MD, Jordan MT, Wen-Qing L, et al. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ health study 2. Allergy. 2017;72(5):831–834. doi: 10.1111/all.13128Aaron M.D., Jordan M.T., Wen-Qing L., et al. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ health study 2 // Allergy. 2017. Vol. 72, N 5. Р. 831–834. doi: 10.1111/all.13128He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. Ann Allergy Asthma Immunol. 2020;124(1):70–78. doi: 10.1016/j.anai.2019.10.013He H., Li R., Choi S., et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis // Ann Allergy Asthma Immunol. 2020. Vol. 124, N 1. Р. 70–78. doi: 10.1016/j.anai.2019.10.013Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70(10):1300–1308. doi: 10.1111/all.12685Silverberg J.I. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies // Allergy. 2015. Vol. 70, N 10. Р. 1300–1308. doi: 10.1111/all.12685Andersen YM, Egeberg A, Gislason GH, et al. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017;76(2):274–280.e1. doi: 10.1016/j.jaad.2016.08.047Andersen Y.M., Egeberg A., Gislason G.H., et al. Autoimmune diseases in adults with atopic dermatitis // J Am Acad Dermatol. 2017. Vol. 76, N 2. Р. 274–280.e1. doi: 10.1016/j.jaad.2016.08.047Ress K, Annus T, Putnik U, et al. Celiac disease in children with atopic dermatitis. Pediatr Dermatol. 2014;31(4):483–488. doi: 10.1111/pde.12372Ress K., Annus T., Putnik U., et al. Celiac disease in children with atopic dermatitis // Pediatr Dermatol. 2014. Vol. 31, N 4. Р. 483–488. doi: 10.1111/pde.12372Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and in"ammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–136. doi: 10.1016/j.jaci.2015.06.029Schmitt J., Schwarz K., Baurecht H., et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and in ammatory bowel disease, and a decreased risk for type 1 diabetes // J Allergy Clin Immunol. 2016. Vol. 137, N 1. Р. 130–136. doi: 10.1016/j.jaci.2015.06.029Pónyai G, Hidvégi B, Németh I, et al. Contact and aeroallergens in adulthood atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1346–1355. doi: 10.1111/j.1468-3083.2008.02886.xPónyai G., Hidvégi B., Németh I., et al. Contact and aeroallergens in adulthood atopic dermatitis // J Eur Acad Dermatol Venereol. 2008. Vol. 22, N 11. Р. 1346–1355. doi: 10.1111/j.1468-3083.2008.02886.xNankervis H, Pynn EV, Boyle RJ, et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015;1(1):CD008426. doi: 10.1002/14651858.CD008426.pub2Nankervis H., Pynn E.V., Boyle R.J., et al. House dust mite reduction and avoidance measures for treating eczema // Cochrane Database Syst Rev. 2015. Vol. 1, N 1. Р. CD008426. doi: 10.1002/14651858.CD008426.pub2Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9. doi: 10.1016/j.jaci.2015.04.015Werfel T., Heratizadeh A., Niebuhr M., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber // J Allergy Clin Immunol. 2015. Vol. 136, N 1. Р. 96–103.e9. doi: 10.1016/j.jaci.2015.04.015Fölster-Holst R, Galecka J, Weißmantel S, et al. Birch pollen influence the severity of atopic eczema: Prospective clinical cohort pilot study and ex vivo penetration study. Clin Cosmet Investig Dermatol. 2015;(8):539–548. doi: 10.2147/CCID.S81700Fölster-Holst R., Galecka J., Weißmantel S., et al. Birch pollen influence the severity of atopic eczema: Prospective clinical cohort pilot study and ex vivo penetration study // Clin Cosmet Investig Dermatol. 2015. N 8. Р. 539–548. doi: 10.2147/CCID.S81700Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131. doi: 10.1016/j.xjidi.2022.100131Beck L.A., Cork M.J., Amagai M., et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis // JID Innov. 2022. Vol. 2, N 5. Р. 100131. doi: 10.1016/j.xjidi.2022.100131Hon KL, Lam PH, Ng WG, et al. Age, sex, and disease status as determinants of skin hydration and transepidermal water loss among children with and without eczema. Hong Kong Med J. 2020;26(1):19–26. doi: 10.12809/hkmj198150Hon K.L., Lam P.H., Ng W.G., et al. Age, sex, and disease status as determinants of skin hydration and transepidermal water loss among children with and without eczema // Hong Kong Med J. 2020. Vol. 26, N 1. Р. 19–26. doi: 10.12809/hkmj198150Horimukai K, Morita K, Narita M, et al. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations. Allergol Int. 2016;65(1):103–108. doi: 10.1016/j.alit.2015.09.004Horimukai K., Morita K., Narita M., et al. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations // Allergol Int. 2016. Vol. 65, N 1. Р. 103–108. doi: 10.1016/j.alit.2015.09.004Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823. doi: 10.1016/j.jaci.2014.08.005Simpson E.L., Chalmers J.R., Hanifin J.M., et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention // J Allergy Clin Immunol. 2014. Vol. 134, N 4. Р. 818–823. doi: 10.1016/j.jaci.2014.08.005Chaoimh NC, Lad D, Nico C, et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants: The STOP-AD randomised controlled trial. Allergy. 2023;78(4):984–994. doi: 10.1111/all.15491Chaoimh N.C., Lad D., Nico C., et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants: The STOP-AD randomised controlled trial // Allergy. 2023. Vol. 78, N 4. Р. 984–994. doi: 10.1111/all.15491Czarnowicki T, Malajian D, Khattri S, et al. Petrolatum: Barrier repair and antimicrobial responses underlying this inert moisturizer. J Allergy Clin Immunol. 2016;137(4):1091–102.e1-7. doi: 10.1016/j.jaci.2015.08.013Czarnowicki T., Malajian D., Khattri S., et al. Petrolatum: Barrier repair and antimicrobial responses underlying this inert moisturizer // J Allergy Clin Immunol. 2016. Vol. 137, N 4. Р. 1091–1102.e1-7. doi: 10.1016/j.jaci.2015.08.013Spada F, Harrison IP, Barnes TM, et al. A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial. Dermatol Ther. 2021;34(4):e14970. doi: 10.1111/dth.14970Spada F., Harrison I.P., Barnes T.M., et al. A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial // Dermatol Ther. 2021. Vol. 34, N 4. Р. e14970. doi: 10.1111/dth.14970Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(Suppl 1):26–34. doi: 10.1111/j.1396-0296.2004.04S1003.xSubramanyan K. Role of mild cleansing in the management of patient skin // Dermatol Ther. 2004. Vol. 17, Suppl. 1. Р. 26–34. doi: 10.1111/j.1396-0296.2004.04S1003.xLitovkina AO, Smolnikov EV, Elisyutina OG, Fedenko ES. Modern emollients in the prevention of exacerbations of atopic dermatitis in the season of flowering. Russ J Allergol. 2023;20(1):41–51. (In Russ). doi: 10.36691/RJA4136Литовкина А.О., Смольников Е.В., Елисютина О.Г., Феденко Е.С. Современные эмоленты в профилактике обострений атопического дерматита в сезон цветения // Российский аллергологический журнал. 2023. Т. 20, № 1. С. 41–51. doi: 10.36691/RJA4136Kubanov AA, Namazova-Baranova LS, Khaitov RM, et al. Atopic dermatitis. Clinical recommendations. Russ Allergol J. 2021;18(3):44–92. (In Russ). doi: 10.36691/RJA1474Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М., и др. Атопический дерматит. Клинические рекомендации // Российский аллергологический журнал. 2021. Т. 18, № 3. C. 44–92. doi: 10.36691/RJA1474